StemCell Therapy

6 February 2012

Angel Biotechnology Holdings plc.

("Angel" or "the Company")

Angel signs three new GMP (KOSDAQ: 018290.KQ - news) manufacturing contracts

for Materia Medica Holding

Angel Biotechnology Holdings plc., (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce that it has reached agreement on three further manufacturing contracts with OOO " NPF "Materia Medica Holding" (MMH) with a combined value in excess of £4.5 million. It is expected these projects will run concurrently and take approximately 22 months to complete.

Under the proposed agreements, Angel will initiate activities within existing facilities, with a view to transferring production to its Cramlington site during 2012, which the Company is currently re-commissioning. The commission of these new agreements will come under the terms of our current umbrella pricing agreement, pending formation of the joint venture company ("JVC") announced on 17 October 2011 after which the contracts will transfer into the control of the JVC.

Dr Paul Harper, Executive Chairman, Angel Biotechnology Holdings, said:

"The commission of these three new agreements provides a robust basis for the proposed JVC between Angel and MMH and demonstrates the confidence the customer has in Angel's capabilities. These agreements will put the proposed JVC on a sure footing from the outset, but is also an excellent example of the value Angel can provide via significant alliances such as this.. I would like to thank MMH for making this commercial commitment."

Professor Oleg Epstein, General Director, OOO "NPF "Materia Medica Holding", said:

"By signing these three new agreements with Angel, MMH can act in a timely manner to bring these products to market. As core business, it is important to us that development work begins whilst the JVC is being established. I am positive this will provide the best possible start to the new JVC.

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Commercial Director http://www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce/Tim Goodman/

Deepak Reddy +44 (0) 20 7947 4350

Media (Frankfurt: 725292 - news) enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc. is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines (Xetra: 938858 - news) and Healthcare products Regulatory Agency (MHRA).

Its (Euronext: ALITS.NX - news) customers range from early-stage biotechnology companies including ReNeuron plc. and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle (Frankfurt: 725198 - news) -upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people.

More information is available at http://www.angelbio.com .

- Ends -

Read more here:
Angel Biotechnology - Contracts with Materia Medica

This entry was posted on February 6, 2012 at 3:07 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |